

GlaxoSmithKline (UK Ltd) and Aneurin Bevan University Health Board Executive Summary

COVID-19 Restart and Recovery- Risk Stratification and review of patients within Primary care with Chronic Obstructive Pulmonary Disease

This summary has been written by GSK with consultation and approval from the Joint Working Project Team.

Aneurin Bevan University Health Board and GSK are undertaking a Joint Working project. The aims are to:

- “Restart and recovery” – provide support to primary care to prioritise and address the backlog of patients, caused by the COVID-19 pandemic, with COPD who are due annual review (appropriately manage current workload more effectively);
- Enable primary care to identify and prioritise patients with defined risk factors, for review (face-to-face or remote) - those patients with an unmet need;
- Support both workforce/resource challenges;
- Optimising management of COPD patients by aligning to the ‘2021 All-Wales COPD Management and Prescribing Guideline’ and ‘NHS Wales Decarbonisation Strategic Delivery Plan’ ABUHB Reducing the environmental Impact of Inhalers: Making the right choice for your patient and the planet; and
- Support primary care to conduct quality COPD reviews (through education).

This involves a balance of contributions from both parties with the pooling of skills, experience and resources. The project will run from December 2021 – December 2022.

Intended Benefits:

Patients	<ul style="list-style-type: none"> • Patients with unmet need are prioritised for a review. • Full COPD review in line with national/local guidelines based on risk stratification (patients may have not received a review otherwise or will receive quicker than when reviewed in yearly cycle) potentially increasing volume of those receiving a review, potentially leading to better outcomes. • Optimisation of both non-pharmacological & pharmacological management. • Potentially fewer COPD- related interventions, including hospital admissions. • Improved patient education as better informed about COPD management and treatment options, as well as about pre-existing educational resources such as NHS Wales COPD HealthHub App • COPD managed in accordance with current best practice clinical guidance. • Better experience of the healthcare system – access to an Interface Clinical Service Clinical pharmacist and/or upskilled primary care clinician at their own GP practice
NHS	<ul style="list-style-type: none"> • Supports “restart and recovery” priorities. • Realisation of value-based healthcare objectives of improved patient outcomes with reduced costs. • Support with risk stratification. • Supports efficiency and effective use of available resources by identifying those patients with unmet need for review. • Additional resource support. • Reduced variability in practice approaches to patient identification and review. • Guideline implementation resulting in consistent prescribing and non-prescribing recommendations and promoting learning for sustainability. • Insight into COPD population at practice and local healthcare economy level to allow sharing best practice and evaluation of care provision to support clinical governance and support equity of care. • Opportunity to upskill primary care doctors and nurses. • An environment to support the delivery of improved health outcomes for the COPD patient population. • Potential reduction in COPD- related interventions, including hospital admissions. • Prescribing in line with national sustainability aspirations where clinically appropriate for patients.
GSK	<ul style="list-style-type: none"> • Broadening of the professional network. • Demonstrate partnership working. • Potential increase in prescribing of on-formulary dry powder inhaler products within class if clinically appropriate for patients, aligned to the sustainability agenda – which may include GSK products. • Expansion of the COPD patient population who are managed according to current clinical and best practice guidelines as a result of the programme. • Increase in the appropriate use of medicines licensed for COPD aligned to local or national guidance, will likely increase the prescribing of GSK products as well as those of other pharmaceutical companies. • Better understanding of the challenges faced by the NHS in delivering high-quality patient services and care. • Helps GSK to live its value of being a patient focussed company.